UBS Group
ENZ

UBS Group’s Enzo Biochem, Inc. ENZ Stock Holding History

UBS Group’s Portfolio ENZ Stock Details ENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-45,713
Closed -$16.9K – 11175
2025
Q1 		$16.9K Buy
45,713
+45,435
+16,344% +$25.1K ﹤0.01% 8338
2024
Q4 		$198 Hold
278
– – ﹤0.01% 9578
2024
Q3 		$311 Sell
278
-445
-62% -$498 ﹤0.01% 9004
2024
Q2 		$788 Buy
723
+445
+160% +$501 ﹤0.01% 8774
2024
Q1 		$353 Sell
278
-1,596
-85% -$2.11K ﹤0.01% 8613
2023
Q4 		$2.6K Buy
+1,874
New +$2.48K ﹤0.01% 8084
2023
Q3 		– Sell
-619
Closed -$1.14K – 10087
2023
Q2 		$1.14K Buy
+619
New +$1.43K ﹤0.01% 8005
2023
Q1 		– Sell
-1,353
Closed -$1.94K – 10580
2022
Q4 		$1.94K Buy
+1,353
New +$2.64K ﹤0.01% 9765
2022
Q3 		– Sell
-425
Closed -$1K – 11067
2022
Q2 		$1K Hold
425
– – ﹤0.01% 10007
2022
Q1 		$1K Sell
425
-2,779
-87% -$8.92K ﹤0.01% 9955
2021
Q4 		$10K Sell
3,204
-1,160
-27% -$3.96K ﹤0.01% 8807
2021
Q3 		$16K Buy
4,364
+3,137
+256% +$10.5K ﹤0.01% 7438
2021
Q2 		$4K Sell
1,227
-7,706
-86% -$24.2K ﹤0.01% 8710
2021
Q1 		$30K Sell
8,933
-4,075
-31% -$12.7K ﹤0.01% 7021
2020
Q4 		$33K Buy
13,008
+6,673
+105% +$14.5K ﹤0.01% 6560
2020
Q3 		$13K Sell
6,335
-8,660
-58% -$20.6K ﹤0.01% 6655
2020
Q2 		$34K Sell
14,995
-13,657
-48% -$35.1K ﹤0.01% 6192
2020
Q1 		$72K Sell
28,652
-29,577
-51% -$72.7K ﹤0.01% 5549
2019
Q4 		$153K Buy
58,229
+9,291
+19% +$27.8K ﹤0.01% 5766
2019
Q3 		$176K Buy
48,938
+28,140
+135% +$99.6K ﹤0.01% 5343
2019
Q2 		$70K Buy
20,798
+6,408
+45% +$22.6K ﹤0.01% 5643
2019
Q1 		$39K Sell
14,390
-18,992
-57% -$62.2K ﹤0.01% 5740
2018
Q4 		$93K Buy
33,382
+8,369
+33% +$27.4K ﹤0.01% 5603
2018
Q3 		$103K Buy
25,013
+2,014
+9% +$9.15K ﹤0.01% 5577
2018
Q2 		$119K Buy
22,999
+7,303
+47% +$44.5K ﹤0.01% 5317
2018
Q1 		$86K Sell
15,696
-5,423
-26% -$38.2K ﹤0.01% 5321
2017
Q4 		$172K Sell
21,119
-26,980
-56% -$258K ﹤0.01% 5021
2017
Q3 		$504K Buy
48,099
+1,322
+3% +$14.7K ﹤0.01% 4211
2017
Q2 		$516K Sell
46,777
-538
-1% -$5.01K ﹤0.01% 4096
2017
Q1 		$396K Sell
47,315
-6,522
-12% -$45.9K ﹤0.01% 4210
2016
Q4 		$373K Buy
53,837
+5,436
+11% +$34.7K ﹤0.01% 4326
2016
Q3 		$246K Buy
48,401
+2,391
+5% +$14.3K ﹤0.01% 4409
2016
Q2 		$275K Sell
46,010
-160,525
-78% -$891K ﹤0.01% 4324
2016
Q1 		$940K Buy
206,535
+159,025
+335% +$708K ﹤0.01% 3313
2015
Q4 		$214K Sell
47,510
-207
-0.4% -$874 ﹤0.01% 4611
2015
Q3 		$152K Sell
47,717
-11,642
-20% -$35.3K ﹤0.01% 4861
2015
Q2 		$179K Buy
59,359
+4,849
+9% +$13.6K ﹤0.01% 4963
2015
Q1 		$161K Buy
54,510
+32,591
+149% +$107K ﹤0.01% 5046
2014
Q4 		$98K Buy
+21,919
New +$105K ﹤0.01% 5721

Other funds holding ENZ

RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
KCM
Kempner Capital Management Galveston, Texas $106M AUM 29.1% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return

UBS Group's ENZ Position: Q2 2025 in Review

UBS Group sold out of Enzo Biochem, Inc. (ENZ) in Q2 2025, closing a stake of 45,713 shares — an estimated $16.9K sold.

UBS Group first reported a position in ENZ in Q4 2014 and held it in 39 quarters. The position peaked at $940K in Q1 2016. 6 funds tracked by Wall St. Rank hold ENZ as of Q2 2025.

  • UBS Group reported no remaining Enzo Biochem, Inc. position as of Q2 2025 after selling out during the quarter.
  • UBS Group sold 45,713 Enzo Biochem, Inc. shares in Q2 2025, an estimated $16.9K.
  • UBS Group first reported a position in Enzo Biochem, Inc. in Q4 2014 and held it in 39 quarters.
  • UBS Group's Enzo Biochem, Inc. position peaked at $940K in Q1 2016.
  • 6 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q2 2025.

Based on UBS Group's 13F filing for Q2 2025, filed 14 Aug 2025.